NeoZanHER phase 2 data in early-stage HER2-positive breast cancer continue to validate zanidatamab as a next-generation approach for pre-surgical treatment. The Nature Communications-published study evaluates zanidatamab in the NeoZanHER phase 2 trial setting designed to move response signals forward in the neoadjuvant window. For companies and trial planners, the work reflects an ongoing shift toward measuring efficacy earlier—before surgery—while refining biomarkers and endpoints for accelerated development in HER2-driven disease.